

1 UNITED STATES PATENT AND TRADEMARK OFFICE

2

3 BEFORE THE PATENT TRIAL AND APPEAL BOARD

4

5 MYLAN PHARMACEUTICALS INC.,

6 Petitioner

7

v.

8

ALLERGAN, INC.,

9

Patent Owner

10

11 Case IPR2016-01127

12 Patent 8,685,930

13 Case IPR2016-01128

14 Patent 8,629,111

15 Case IPR2016-01129

16 Patent 8,642,556

17 Case IPR2016-01130

18 Patent 8,633,162

19 Case IPR2016-01131

20 Patent 8,648,048

21 Case IPR2016-01132

22 Patent 9,248,191

23

24 DEPOSITION OF MANSOOR AMIJI, Ph.D.

25 Wednesday, February 22, 2017 9:10 a.m.

Page 2

1 Fish & Richardson P.C.  
 2 One Marina Park Drive, Boston, MA 02210  
 3  
 4 Reported by:  
 5 Janet Sambataro, RMR, CRR, CLR  
 6 JOB NO. LA-115711  
 7  
 8  
 9 February 22, 2017  
 10 9:10 a.m.  
 11  
 12  
 13 Deposition of MANSOOR AMIJI, PH.D., held  
 14 at the offices of Fish & Richardson P.C., One  
 15 Marina Park Drive, Boston, Massachusetts,  
 16 pursuant to Agreement before Janet Sambataro, a  
 17 Registered Merit Reporter, Certified Realtime  
 18 Reporter, Certified LiveNote Reporter, and a  
 19 Notary Public within and for the Commonwealth of  
 20 Massachusetts.  
 21  
 22  
 23  
 24  
 25

Page 3

1 APPEARANCES:  
 2 FISH & RICHARDSON P.C.  
 3 (By Susan Morrison Coletti, Esquire)  
 4 222 Delaware Avenue  
 5 Wilmington, Delaware 19899  
 6 302.652.5070  
 7 coletti@fr.com  
 8 Counsel for the Petitioner  
 9 - and -  
 10 FISH & RICHARDSON P.C.  
 11 (By Tasha M. Francis, Ph.D., Esquire)  
 12 3200 RBC Plaza  
 13 60 South Sixth Street  
 14 Minneapolis, Minnesota 55402  
 15 612.335.5070  
 16 Counsel for the Petitioner  
 17  
 18 WILSON SONSINI GOODRICH & ROSATI  
 19 (By Jad Mills, Esquire)  
 20 701 Fifth Avenue, Suite 5100  
 21 Seattle, Washington 98104  
 22 206.883.2554  
 23 jmills@wsgr.com  
 24 Counsel for the Respondent  
 25

Page 4

I N D E X

2 WITNESS DIRECT CROSS REDIRECT  
 3 MANSOOR AMIJI, Ph.D.  
 4 By Ms. Coletti 5  
 5  
 6  
 7 PREVIOUSLY MARKED EXHIBITS

Number	Page
9 Exhibit 1001	44
10 Exhibit 1002 in IPR 2016-01129	16
11 Exhibit 1002 in IPR 2016-01128	16
12 Exhibit 1002 in IPR 2016-01129	16
13 Exhibit 1002 in IPR 2016-01130	17
14 Exhibit 1002 in IPR 2016-01131	17
15 Exhibit 1002 in IPR 2016-01132	17
16 Exhibit 1003	18
17 Exhibit 1004	44
18 Exhibit 1006	46
19 Exhibit 1007	47
20 Exhibit 1008	47
21 Exhibit 1009	162
22 Exhibit 1015	106
23	
24	
25	

Page 5

P R O C E E D I N G S

2 MANSOOR AMIJI, Ph.D.,  
 3 having been duly sworn, after presenting  
 4 identification in the form of a driver's license,  
 5 deposes and says as follows:  
 6 DIRECT EXAMINATION  
 7 BY MS. COLETTI:  
 8 Q. Good morning, Dr. Amiji.  
 9 A. Good morning.  
 10 Q. Can you please state and spell your  
 11 name for the record.  
 12 A. Mansoor, spelled M-A-N-S-O-O-R, middle  
 13 initial M., as in Mary, last name A-M-I-J-I.  
 14 Q. And can you please state your business  
 15 address.  
 16 A. Northeastern University, 360 Huntington  
 17 Avenue, Boston, Massachusetts 02115.  
 18 Q. Now, before I get started into the  
 19 substance of today's deposition, I'll go over a  
 20 few ground rules.  
 21 I believe you've been deposed before. Is  
 22 that right?  
 23 A. Yes.  
 24 Q. So you probably know some of these, but  
 25 I'll go over them anyway.

Page 6

1 You understand you're under oath. The court  
 2 reporter just swore you in. Right?  
 3 A. Yes.  
 4 Q. And you understand that any testimony  
 5 that you give today can be used in the IPR  
 6 proceeding that we're here today talking about.  
 7 You understand that. Right?  
 8 A. Yes.  
 9 Q. And you understand that the testimony  
 10 that you give today is the same as if you were  
 11 giving it in court.  
 12 Do you understand that as well?  
 13 A. Yes.  
 14 Q. And so you understand that it's  
 15 important to testify completely and truthfully  
 16 and accurately. Right?  
 17 A. Yes.  
 18 Q. Because our court reporter here is  
 19 recording our conversation, it's important that  
 20 you verbalize your answers, so "yes" or "no" as  
 21 opposed to nodding or shaking your head. Do you  
 22 understand that?  
 23 A. Yes.  
 24 Q. And it's important that we don't speak  
 25 over each other. So I will try to let you finish

Page 7

1 an answer before I ask my next question, and I'd  
 2 ask that you allow me to finish my question  
 3 before you give your answer. Is that okay?  
 4 A. Yes.  
 5 Q. Your attorney may object from time to  
 6 time, but unless for some reason he instructs you  
 7 not to answer the question, do you understand  
 8 you're obligated to answer my question as best  
 9 you can?  
 10 A. Yes.  
 11 Q. If one of my questions is confusing or  
 12 if you need some clarification, please let me  
 13 know and I'll try to rephrase it. Okay?  
 14 A. Yes.  
 15 Q. So then is it fair to assume that if  
 16 you answer my question, that you've understood  
 17 it?  
 18 A. Yes.  
 19 Q. Dr. Amiji, is there any reason, medical  
 20 or otherwise, that you can't give complete,  
 21 truthful and accurate testimony today?  
 22 A. No.  
 23 Q. And if that ever changes during the  
 24 course of the day, if you start to feel ill, just  
 25 let me know. Is that okay?

Page 8

1 A. Sure.  
 2 Q. Now, I think you said already you have  
 3 been deposed before. Is that correct?  
 4 A. Yes.  
 5 Q. About how many times?  
 6 A. Five or six times.  
 7 Q. And always as an expert witness or in  
 8 other capacities as well?  
 9 A. In some of the cases, I've -- in other  
 10 capacities as well.  
 11 Q. And let's talk about the expert witness  
 12 work first. What sorts of cases were they? Were  
 13 they all patent infringements? Were there other  
 14 kinds of cases in which you testified as an  
 15 expert?  
 16 A. Some were patent infringement. There  
 17 are also other types of cases.  
 18 Q. What were the other types?  
 19 A. Contract disputes.  
 20 Q. Okay. What else?  
 21 A. There was also one case that involved a  
 22 university that was -- the plaintiffs were  
 23 St. John's University, and they were suing and I  
 24 was asked to serve as an expert to look at the  
 25 technical aspect of the case.

Page 9

1 Q. What was the dispute about in that  
 2 case? Do you recall?  
 3 A. It involved patents, but not  
 4 necessarily from infringement side. It was just  
 5 the patents and who were the owners, the rightful  
 6 owners of the patents.  
 7 Q. I see. And what about cases where you  
 8 were not serving as an expert witness? What  
 9 sorts of cases were those? I think you said you  
 10 were deposed in cases where you were not an  
 11 expert witness. Is that right?  
 12 A. No. I'm not sure I said that.  
 13 Q. Maybe I misunderstood you, then. So in  
 14 all these five or six depositions that you gave,  
 15 you were always an expert witness. Is that  
 16 right?  
 17 A. Yes. I was asked to serve as an expert  
 18 looking at the technical matters.  
 19 Q. Okay. When was the last time you were  
 20 deposed?  
 21 A. November of last year.  
 22 Q. And what did that relate to, generally?  
 23 Was that a patent infringement case?  
 24 A. Yes.  
 25 Q. What was the technology, generally?

Page 10

1 A. It was a drug formulation patent.

2 Q. Was it a Hatch-Waxman case or ANDA

3 case?

4 A. Yes.

5 Q. Have you ever been deposed in an IPR

6 proceeding before?

7 A. No, I haven't.

8 Q. Have you ever served as an expert

9 witness in an IPR proceeding, before this one?

10 A. Yeah. I don't believe I have served on

11 an IPR proceeding before.

12 Q. In all of the cases where you were --

13 excuse me, in all of the patent cases where you

14 served as an expert witness, were they all

15 Hatch-Waxman cases?

16 A. No. As I said before, I have served on

17 cases like the St. John's case I mentioned, which

18 also involved patents, but it wasn't a

19 Hatch-Waxman case.

20 Q. But that wasn't a patent infringement

21 case? Is that right?

22 A. No. It wasn't a patent infringement.

23 Q. So limiting it just to the patent

24 infringement cases that you have served as an

25 expert on, were all of those Hatch-Waxman cases?

Page 11

1 A. Yes.

2 Q. And have you ever been an expert

3 witness in a case related to ophthalmic drugs

4 before?

5 A. No, I have not.

6 Q. Did you do anything to prepare for

7 today's deposition?

8 A. Yes.

9 Q. What did you do?

10 A. I read my declarations. I read

11 patents. I read the prosecution history. I read

12 a lot of documents.

13 Q. Did you meet with anyone to prepare for

14 today's deposition?

15 A. Yes.

16 Q. Who did you meet with?

17 A. With attorneys.

18 Q. When did you do that?

19 A. The day before yesterday and yesterday.

20 Q. For about how long?

21 A. Just a few hours both days.

22 Q. A few hours each day?

23 A. Yes.

24 Q. About how many?

25 A. Maybe five or six hours.

Page 12

1 Q. So a good chunk of the business day.

2 Is that fair?

3 A. Yeah.

4 Q. And which lawyers were present? The

5 lawyers that are here?

6 A. Yes. All three of them.

7 Q. All three of them. Was anyone else

8 present?

9 A. Mr. Parmelee was on the call yesterday,

10 just for a few -- maybe an hour or so.

11 Q. Was anyone else present in the room

12 with you and the lawyers yesterday or the day

13 before when you were preparing for the

14 deposition?

15 A. No.

16 Q. And did you speak to anyone else, other

17 than lawyers, in preparation for your deposition?

18 A. No.

19 Q. You said you read the patents, the

20 prosecution histories. What other documents did

21 you read besides those?

22 A. The declarations, my declarations. I

23 also reviewed some of the exhibits that are

24 attached to the declarations.

25 Q. Was there anything outside the

Page 13

1 declarations, the attachments, and the patents

2 that you reviewed? So anything that you didn't

3 cite in your declarations?

4 A. No.

5 Q. Okay. And did you review those on your

6 own or did you review them with the lawyers or

7 both?

8 A. Some of it I reviewed on my own.

9 Sometimes we would have some discussions, and

10 we'd do it together.

11 Q. And when did you start preparing for

12 the deposition?

13 A. Maybe about two weeks ago.

14 Q. Did you read all of your declarations

15 again or did you focus on any one in particular?

16 A. No. I read all, and specifically

17 looking at all. I also looked at the IPR

18 decision that came from the patent board.

19 Q. The institution decision?

20 A. Correct.

21 Q. Is that what you mean?

22 A. Yes.

23 Q. Do you understand, Dr. Amiji, that

24 there is a concurrent litigation going on between

25 Allergan and Mylan or Restasis in District Court?

Page 14

1 A. I was informed of that a long time ago,  
 2 but I haven't really had any interactions on  
 3 that.  
 4 Q. Do you know anything about that  
 5 litigation?  
 6 A. No, I don't.  
 7 Q. Have you reviewed any documents or  
 8 court orders from that proceeding?  
 9 A. No.  
 10 Q. Has anyone talked to you about any  
 11 documents or court orders from that proceeding?  
 12 MR. MILLS: I'm just going to register  
 13 an objection on the basis of privilege and  
 14 attorney work product. And to the extent that  
 15 the question inquires into any conversations with  
 16 counsel, then I would instruct you to not answer  
 17 with regards to conversations with counsel.  
 18 MS. COLETTI: Dr. Amiji is an expert  
 19 witness. There is no privilege between lawyers  
 20 and an expert witness. So I think that's an  
 21 improper instruction.  
 22 BY MS. COLETTI:  
 23 Q. So did anyone tell you anything about  
 24 the Court orders or the proceedings in the  
 25 District Court?

Page 15

1 A. No.  
 2 MR. MILLS: Same instruction.  
 3 Q. And have you asked for any documents  
 4 from that proceeding? You said you didn't review  
 5 anything.  
 6 Have you asked for anything but not gotten  
 7 it?  
 8 A. No.  
 9 Q. Do you know anything about Mylan's ANDA  
 10 or Mylan's generic product?  
 11 A. No.  
 12 Q. Do you know anything about any of the  
 13 other -- let me step back a minute.  
 14 Do you know anything about whether there are  
 15 other generic companies attempting to make  
 16 generic versions of Restasis?  
 17 A. No, I don't.  
 18 Q. Have you been contacted by lawyers for  
 19 any of the other generic companies regarding  
 20 Restasis?  
 21 A. No, I have not.  
 22 Q. And do you know the status of Mylan's  
 23 ANDA with FDA?  
 24 A. No, I don't.  
 25 Q. So fair to say you don't know whether

Page 16

1 Mylan's ANDA has been approved or not?  
 2 A. No, I don't.  
 3 Q. And you don't have any knowledge  
 4 regarding any problems Mylan may or may not be  
 5 having with its ANDA. Is that right?  
 6 A. That's right.  
 7 Q. And have you been asked to serve as an  
 8 expert witness in the District Court litigation?  
 9 A. No, I have not.  
 10 Q. Okay. I'm going to hand you,  
 11 Dr. Amiji, and I'm going to read them one by one,  
 12 but these are all your declarations but so our  
 13 record is clear.  
 14 So first I have what has been marked as  
 15 Exhibit 1002 in IPR 2016-01127, and it's your  
 16 declaration related to the '930 patent.  
 17 Then I'm going to hand you what's been  
 18 marked as Exhibit 1002 in IPR 2016-01128. It's  
 19 your declaration related to the '111 patent.  
 20 MR. MILLS: Do you have copies of any  
 21 of these documents?  
 22 MS. COLETTI: I do. I'll hand you a  
 23 whole pile in just a moment.  
 24 Q. Next I have what's been marked as  
 25 Exhibit 1002 in IPR 2016-01129. It's your

Page 17

1 declaration related to the '556 patent.  
 2 Then I've got what has been marked as  
 3 Exhibit 1002 in IPR 2016-01130. It's your  
 4 declaration related to the '162 patent.  
 5 Next is Exhibit 1002 in IPR 2016-01131.  
 6 It's your declaration related to the '048 patent.  
 7 And then finally, Exhibit 1002 in IPR 2016-01132.  
 8 It's your declaration related to the '191 patent.  
 9 And, Dr. Amiji, you have your six  
 10 declarations in front of you? Are all of those  
 11 in front of you?  
 12 A. Yes.  
 13 Q. For purposes of today's questioning,  
 14 I'm going to focus mostly on the second document  
 15 we marked. It's the one for the '111 patent. So  
 16 if you'd like to reference any of the others, you  
 17 have all of them. But that's the one I'm going  
 18 to spend most of my time questioning on.  
 19 And I see, Dr. Amiji, you have a binder of  
 20 documents in front of you. What's in your binder  
 21 that you brought with you today?  
 22 A. So that's the same, the declarations  
 23 and then the corresponding patents.  
 24 Q. Okay. And is there anything in your  
 25 binder that's marked up or in any way is

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.